01—Abstract
Summary
Summary of the 10-K filed March 26, 2001. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals' FY2000 10-K shows a company in a major investment and expansion phase, funded heavily by new capital and partner payments rather than operations.
Total revenues rose to $78.1 milliona in 2000 from $50.6 million in 1999, but the net loss widened to $39.7 million ($0.73 per share), including a $14.4 million make-whole charge on redeemed convertible notes and a $3.2 million non-cash cumulative effect charge from adopting SAB 101. Only $12.0 million of revenue came from royalties and product sales (Agenerase), while $66.1 million came from collaborative and R&D arrangements, so the company still depends on partner funding for much of its income. The balance sheet changed significantly.
Cash and investments grew to $707.4 millionb after the issuance of $520 million in 5% convertible subordinated notes in March and September 2000, and about $170 million of the March notes converted into equity. Long-term debt is now $345 million in convertible notes, and management expects operating losses to continue beyond 2001 as research and development spending rises. Management states current funds are sufficient for at least 18 months.
The pipeline is broad but early. Agenerase (amprenavir), marketed by GlaxoSmithKline, is the only approved product, with about 8%c U.S. protease inhibitor share.
Vertex has one Phase III candidate (VX-175), several Phase II programs (VX-497, VX-740 with Aventis, VX-745, Incel, timcodar), and a Novartis kinase collaboration worth up to roughly $600 milliond in pre-commercial payments. Key risks include dependence on partners, competition in HIV and RA markets, reliance on third-party manufacturing, a patent suit by Chiron, and high share price volatility, which ranged from $11.68 to $99.25 during 2000.
02—Key points
Key Highlights
- Total revenues rose 55% to $78.1 million in 2000, but the net loss widened to $39.7 million ($0.73 per share) from $41.0 million in 1999 on a per-share basis, with a $14.4 million debt conversion charge and a $3.2 million SAB 101 cumulative effect charge.
- Cash, cash equivalents and investments increased to $707.4 million at year-end 2000 from $187.8 million, driven by $520 million of convertible subordinated note issuances.
- Agenerase (amprenavir) is the only approved product, generating $12.0 million in royalty and product sales; it held roughly 8% of U.S. HIV protease inhibitor prescriptions as of December 31, 2000.
- The Novartis kinase collaboration (May 2000) offers up to approximately $600 million in pre-commercial payments, including a $200 million interest-free loan facility, and drove most of the increase in collaborative revenue.
- Long-term debt rose to $345 million of 5% convertible subordinated notes due 2007 after the March notes were called and mostly converted into common stock.
- The pipeline includes 12 drug candidates, with VX-175 (HIV, Phase III) the most advanced, and several Phase II programs in hepatitis C, rheumatoid arthritis, oncology, and neurology.
- Management expects operating losses to continue beyond 2001 and says current funds are sufficient for at least 18 months; the stock traded between $11.68 and $99.25 during 2000.
03—Questions
Frequently Asked Questions
Is Vertex profitable, and what drove the 2000 net loss?
No. Vertex reported a 2000 net loss of $39.7 million, or $0.73 per share, versus $41.0 million, or $0.80 per share, in 1999. The loss included a one-time $14.4 million make-whole payment to holders of the redeemed March 2007 convertible notes and a $3.2 million non-cash charge from adopting SAB 101. Management expects operating losses to continue beyond 2001 as it expands research and development.
How much of Vertex's revenue comes from its own products?
Very little. Royalties and product sales were $12.0 million of the $78.1 million total in 2000. The remaining $66.1 million came from collaborative and other R&D revenue, mainly from partners such as Novartis, Aventis, Serono, and Taisho. Revenue from these partners depends on their continued funding and on milestones being achieved.
Is Vertex's cash position sufficient to fund operations?
Management says its funds are sufficient for at least 18 months. Cash and investments were $707.4 million at year-end 2000, but the company is also carrying $345 million of convertible notes and expects rising R&D costs. It may need additional financing if partner payments are delayed or the pipeline requires more capital.
What are the main risks to investors?
The main risks include dependence on collaborative partners, which can terminate agreements on notice; competition from larger pharmaceutical companies in HIV, hepatitis C, and rheumatoid arthritis; reliance on third-party manufacturers; the Chiron patent infringement suit; and high stock price volatility. Agenerase sales may also decline as treatment strategies change, and GlaxoSmithKline controls most of its marketing.
What is the outlook for Agenerase and the pipeline?
Agenerase is marketed by GlaxoSmithKline and co-promoted by Vertex. Its European launch was recent and its U.S. share may decline. The pipeline's most advanced asset, VX-175 (a prodrug of amprenavir), began two Phase III trials in November 2000, and VX-740 (pralnacasan) is in Phase II for rheumatoid arthritis with Aventis. Clinical and regulatory outcomes for these candidates remain uncertain.
04—Continue